Zulin

Quick links to important sections

Zulin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zulin

What is Zulin? (Mirtazapine Overview)

Zulin is a prescription-only medication whose active ingredient is Mirtazapine, a synthetically derived chemical compound used to help stabilize and improve mood in adults. It is classified as an Antidepressant, providing a unique pharmacological option for individuals needing support for their emotional balance.


Quick Facts: Zulin

Property Description
Active Ingredient Mirtazapine
Form Tablet, Orally Disintegrating Tablet (ODT), Liquid Solution
Pharmacological Class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common Type Atypical Antidepressant
Origin Synthetic Compound

What Type of Medicine is Zulin and What Does it Contain?

Zulin is categorized as an Atypical Antidepressant and is a single-ingredient product containing the pure, synthetic compound Mirtazapine. The synthetic origin of Mirtazapine ensures a highly consistent and predictable profile of action. Zulin is supplied for oral administration in several dosage forms, including conventional Tablets, rapid-acting Orally Disintegrating Tablets (ODT), and a Liquid Solution. The ODT form, for example, is clinically recognized for its utility in patients who may have difficulty swallowing tablets, ensuring compliance.


Zulin’s Unique Pharmacological Classification and General Purpose

Zulin is specifically categorized as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA), a unique classification that denotes its dual functionality on key brain chemicals. This classification distinguishes Zulin from more common antidepressant types, such as Selective Serotonin Reuptake Inhibitors (SSRIs), by promoting the release of both Serotonin and Norepinephrine through indirect modulation. Mirtazapine's mechanism promotes the increased availability of these neurotransmitters. This mechanism is often utilized when an individual requires help not only with mood but also with concurrent sleep disturbances, a common neutral use scenario. The general therapeutic purpose of Zulin is to help individuals restore a functional emotional baseline, alleviating feelings of persistent low mood.


Conceptual Note on Mirtazapine's Dual Functionality

The NaSSA classification highlights a strategic dual mode of action that enhances two critical neurotransmitters, Serotonin and Norepinephrine, setting it apart from single-target agents.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Zulin?

Possible Side Effects and Safety Information

The safety profile of Zulin, whose active ingredient is Mirtazapine, is officially classified by government regulatory authorities based on the frequency and system-organ class affected. This classification establishes the expected profile and highlights specific areas for caution.


Official Frequency of Adverse Reactions

Adverse reactions are grouped by their documented rate of occurrence in regulatory information:

Classification Examples of Documented Reactions
Very Common (1/10) Somnolence/Sedation, Increased Appetite, Weight Gain, Dry Mouth.
Common (< 1/10 to 1/100) Headache, Dizziness, Lethargy, Tremor, Nausea, Constipation, Peripheral Edema, Orthostatic Hypotension, Abnormal Dreams, Anxiety.

Serious Adverse Reactions and Systemic Concerns

The official labeling documents rare but clinically critical reactions. These include Agranulocytosis (a severe decrease in white blood cells) and the potential for Serotonin Syndrome, a serious condition associated with increased serotonergic activity. Furthermore, regulatory agencies note the risk of Suicidal Thoughts and Behaviors, particularly at the initiation of therapy or following dose adjustments, especially in young adults.

Safety characteristics are also noted for specific groups. Clearance of Mirtazapine is officially documented as reduced in older adults and in patients with severe renal or hepatic impairment, necessitating careful consideration in these populations. The safety and effectiveness of the medicine are not established for individuals under 18 years of age.

Overdose and Emergency Response

Overdose and when to seek help

Overdose information documented in regulatory sources indicates that manifestations may include central nervous system effects such as drowsiness (somnolence), disorientation, and impaired memory, alongside a fast heart rate (tachycardia). Immediate medical attention is required whenever an overdose is suspected because of the potential for serious outcomes. These severe, regulator-documented risks include QT prolongation and Torsades de Pointes (a serious heart rhythm abnormality), as well as Serotonin Syndrome. Severe outcomes, including fatalities, have occurred, particularly in cases where Zulin was ingested in a mixed overdose with other agents.


Management must consist of general measures employed for antidepressant overdose. No specific antidotes for Mirtazapine are known, confirming that treatment must be symptomatic and supportive. Required actions include ensuring an adequate airway, oxygenation, and ventilation, and the mandated monitoring of cardiac rhythm and vital signs. Supportive procedures documented include administering activated charcoal and considering gastric lavage with proper airway protection; the induction of emesis is officially not recommended.

Therapeutic Uses of Zulin

What Zulin Treats: Main Uses and Benefits

Zulin is commonly used in situations involving certain distressing symptoms related to mood disorders, and is commonly used to help with difficult episodes. It is relevant in clinical settings marked by heightened patient distress and the clustering of disruptive symptom manifestations. The core therapeutic use is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

The medication is applied across therapeutic domains involving core depression symptoms, co-occurring sleep disturbances, and appetite loss. It is commonly applied in contexts where additional support for symptom management is needed for co-occurring insomnia and anxiety. This provides supportive relief that contributes to improved day-to-day comfort. Zulin may assist with easing the overall symptom load during difficult episodes, and is considered relevant in conditions where symptoms of depression may lead to disruptions in appetite or unintended weight loss.


Quick Fact: Symptomatic Support

Symptom Domain Primary Therapeutic Benefit
Persistent Low Mood Helps support the patient in improving functional stability.
Sleep Disturbances Contributes to improved day-to-day comfort and stability.
Appetite Loss Assists with maintaining functional stability and general well-being.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Zulin (Mirtazapine) — Official Regulatory Information

This section details the official population eligibility and non-eligibility rules for Zulin as defined in governmental regulatory documents.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults for the treatment of Major Depressive Disorder (MDD).
Populations for whom use is contraindicated Patients with known hypersensitivity to Mirtazapine or any excipients.
Patients receiving, or within 14 days of discontinuing, a Monoamine Oxidase Inhibitor (MAOI).
Age-related eligibility rules Adults (18 years and older) are the approved population. Safety and effectiveness are not established for pediatric patients (under 18 years); use is not recommended.
Condition-specific eligibility rules Caution is indicated for patients with moderate to severe renal impairment or hepatic impairment due to potential reduced drug clearance.
Pregnancy and lactation eligibility status Pregnancy: Use is generally not recommended unless clearly needed. Lactation: Use is not recommended; a decision must be made to discontinue the drug or nursing.

Eligibility-Related Restrictions

Use requires caution or specific consideration in: Older adults (Geriatric), due to potential reduced clearance; patients with a history of seizure disorders; and individuals with conditions that could predispose them to hypotension.


Connection to the overall eligibility profile Regulatory documents strictly define the use of Zulin in adults as the approved population. The official profile is established by absolute exclusions (contraindications) and specific conditional-use classifications for groups like children, older adults, and individuals with specific organ impairments. This framework dictates who is prohibited from using the medicine and who requires restricted use under defined regulatory conditions.

What should I know about interactions with other medicines?

Zulin’s official interaction profile is structured by pharmacokinetic and pharmacodynamic effects, establishing clear restrictions documented in regulatory labeling.

Contraindicated Combinations and Timing Rules

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), including agents such as Linezolid and injectable Methylene Blue, due to the significant risk of Serotonin Syndrome. A mandatory washout period of at least 14 days is required when switching between Zulin and an MAOI.

Pharmacokinetic Interactions (Exposure)

The medicine is metabolized by multiple CYP enzymes, notably CYP3A4, CYP2D6, and CYP1A2. Substances that inhibit these enzymes, such as Ketoconazole (a strong CYP3A4 inhibitor) or Cimetidine, formally increase Zulin plasma concentrations. Conversely, strong CYP3A4 inducers like Carbamazepine or Phenytoin decrease Zulin exposure by increasing its clearance.

Pharmacodynamic Interactions and Substance Cautions

Concurrent use with other serotonergic drugs (e.g., Triptans, SSRIs) may result in an additive effect, increasing the risk of serotonergic adverse events. An additive pharmacodynamic effect is documented with CNS depressants and alcohol (ethanol), which potentiates impaired cognitive and motor function. The herbal supplement St. John's Wort is noted for increasing serotonergic effects. Regulatory documents also note a small increase in the International Normalized Ratio (INR) when Zulin is co-administered with Warfarin. Clearance may be decreased in patients with hepatic or severe renal impairment, affecting exposure.

Mechanism of Action

️ Dual Neurotransmitter Disinhibition

Zulin's core mechanism begins with the antagonism of presynaptic mathbfalpha2 -adrenergic autoreceptors and heteroreceptors. These receptors regulate the release of Norepinephrine and Serotonin (5-HT) by maintaining inhibitory feedback. By blocking this regulation, Zulin disinhibits the release of both neurotransmitters, increasing their availability to postsynaptic receptors. This dual enhancement of monoamine signaling modulates the activity within key central neural circuits.


Specific Serotonin Pathway Modulation

The increased Serotonin is then specifically channeled due to Zulin's antagonist activity at the postsynaptic mathbf5- HT2 and mathbf5- HT3 receptors. This blockade prevents Serotonin from signaling through these specific subtypes and effectively redirects it toward the mathbf5- HT1 A receptors. This functional selectivity results in a targeted pattern of Serotonin activity that influences complex central signaling. The mathbf5- HT3 receptor antagonism also modulates signaling in the gastrointestinal pathway.


Central Histamine mathbfH1 Blockade

Zulin is an antagonist of central Histamine mathbf H1 receptors, molecular targets that mediate arousal and wakefulness. Since Zulin has a high affinity for the H1 receptor, this blocking action is functionally dominant, particularly at lower concentrations. The resulting suppression of histaminergic signaling modulates neural pathways governing the arousal/wakefulness cycle and influences signaling associated with metabolic regulation. The physiological consequence is a central nervous system depressant effect.

Dosage and Administration Information

How Zulin is used

Zulin is supplied for oral administration only, available as Film-Coated Tablets, Orally Disintegrating Tablets (ODT), and Oral Solution. Use must adhere strictly to established guidelines for dose, frequency, and administration.


Official Dosing and Administration

The standard regimen for adult use is summarized below:

Usage Parameter Instruction (Adults)
Route & Forms Oral route: Tablet, ODT, or Solution. Tablets are swallowed whole; ODTs are placed on the tongue to dissolve.
Starting Dose Typically 15 mg once daily.
Maintenance Range Usually 15 mg to 45 mg per day.
Maximum Dose 45 mg per day.
Frequency & Timing Once daily, preferably as a single dose in the evening before sleep.

Specific Use Instructions

Dose Adjustment: Changes to the dose should only be made in intervals of no less than 1 to 2 weeks to allow sufficient time to evaluate the response.

Administration Conditions: Film-coated tablets may be taken with or without food. Orally Disintegrating Tablets (ODT) should be handled with dry hands and used immediately after removal from the blister; they must not be chewed or crushed.

Population-Specific Rules:

  • Older Adults: A lower starting dose (e.g., 7.5 mg) is often recommended, and dose increases should proceed under close professional supervision.
  • Renal/Hepatic Impairment: A dosage decrease may be necessary in patients with moderate to severe renal or hepatic impairment.
  • Pediatric Population: The medicine is generally not recommended for use in children and adolescents under 18 years.

Discontinuation: Treatment should be stopped gradually by reducing the dose over time.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zulin


Evidence for Use in Major Depressive Disorder (MDD)

The core research base for Major Depressive Disorder (MDD) involves numerous short-term randomized, placebo-controlled trials (RCTs) where Zulin was evaluated in adult outpatients experiencing conditions characterized by fluctuating or episodic manifestations. This research was studied for exploring how symptoms change over time compared to an inactive substance. These trials focused on outcomes reflecting daily functioning or activity level, such as tracking how symptoms evolved in the observed populations by measuring changes in standardized severity scores.

Research also examined Zulin in comparative trials against other medications. Studies report how symptoms evolved in the observed populations when compared to placebo or other treatments over the short-term study period. Evidence for long-term was observed in continuation studies, but follow-up durations were limited in continuation studies, which generally extended to nine months.


Research on Concurrent Symptoms (Anxiety, Sleep, and Appetite)

Zulin was evaluated in research exploring how symptoms change over time for patients whose MDD conditions are associated with acute or disruptive episodes of concurrent symptoms, such as sleep disturbance, anxiety, or appetite loss. This evidence often stems from detailed subgroup analyses that re-examined the data collected in the original MDD RCTs.

Studies monitored specific outcomes related to physical discomfort and patient-reported outcomes describing perceived symptom severity. Research examined changes in body weight, which was associated with the medicine in some trials. Studies report how symptoms evolved in the observed populations with sleep disturbance factor scores, comparing measurements against placebo or other treatments.


Research Gaps and Areas of Uncertainty

Follow-up durations were limited in the primary placebo-controlled trials, meaning knowledge of long-term outcomes is not well characterized. Research currently provides context but not individual predictions regarding sustained symptom stability beyond the typical study window.

Data for certain groups remain insufficient. The medicine was not studied for use in children or adolescents; therefore, data for these groups remain insufficient. Scientific literature confirms that the evidence quality varies across studies, particularly for findings derived from subgroup or secondary analyses focusing on specific symptoms.

Frequently Asked Questions (FAQ)

Common questions about Zulin (FAQ)


Q: How quickly does Zulin start working?

Clinical studies often assess response over several weeks. While some individuals may begin to see changes within the first two weeks, the full therapeutic benefit generally develops gradually over one to two months. Healthcare providers typically use this time frame when assessing the need for dose adjustments.


Q: Are there generic versions of Zulin available?

Yes, Zulin is the brand name for the active ingredient Mirtazapine. According to official drug status listings, the active ingredient is available as a generic medication.


Q: Does Zulin require a prescription?

Yes, Zulin is classified as a prescription-only medication. The medicine is dispensed by a pharmacist upon presentation of a valid prescription.


Q: Why is Zulin sometimes prescribed for long-term use?

Official guidelines often recommend that antidepressant treatment be continued for a sufficient period after a satisfactory response is achieved. This continuation is generally recommended to help maintain the treatment response and may reduce the risk of the underlying condition recurring.


Q: Does taking Zulin affect my liver function tests?

Official information notes that some patients have experienced temporary, generally modest, elevations in liver enzyme levels during treatment. There have been rare reports of more serious liver injury following use.


Q: Are there any less common, but serious, side effects of Zulin I should know about?

Official labeling highlights several serious but rare adverse reactions. These include a severe decrease in white blood cells (Agranulocytosis) and the potential for Serotonin Syndrome, which is a serious condition related to high levels of serotonin activity.


Q: Can I take Zulin if I have diabetes?

Official reports indicate that Zulin use has been associated with metabolic effects, including changes to blood lipids and cholesterol. Abnormal blood sugar levels (diabetes mellitus) have also been reported in some cases during post-marketing use.


Q: Why do doctors prefer Zulin for certain conditions?

Zulin has a distinct pharmacological classification as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This unique profile means it works by indirectly enhancing the release of two key brain chemicals, Serotonin and Norepinephrine, setting it apart from other types of medications.


Q: What are the storage instructions for Zulin?

According to official regulatory documents, Zulin must be kept at a controlled room temperature, generally below 30 C, and protected from light and moisture. The medicine should be maintained in its original packaging and kept out of the sight and reach of children for safety.


Q: Does Zulin come in different strengths?

Yes, Zulin is available in multiple formulations and strengths, which are confirmed in the official product information. These may include several different tablet strengths that are available to healthcare providers for prescribing.


Q: Are Zulin side effects worse at the beginning of treatment?

The risk of specific adverse effects, particularly suicidal thoughts and behaviors, is noted to be higher when treatment is initiated or when the dose is adjusted. Additionally, common side effects like drowsiness (somnolence) are sometimes more noticeable at the start of therapy or when lower doses are used.


Q: Can Zulin interact with herbal remedies?

Official drug interaction information specifically cautions against co-administration with the herbal supplement St. John's Wort. Co-administration may lead to an increased risk of developing serotonergic adverse events.


Q: Is Zulin a new or established medication?

Zulin (Mirtazapine) is an established medication. The active ingredient received its initial approval from the FDA in 1996.


Q: Can people with high blood pressure take Zulin?

Zulin has the potential to cause orthostatic hypotension, which is a drop in blood pressure when standing up. Official guidance indicates caution is warranted for patients with known cardiovascular diseases or other conditions that may predispose them to low blood pressure.


Q: Does Zulin affect sleep patterns?

The drug's blocking action on central Histamine H1 receptors is associated with its prominent sedative effect. For this reason, drowsiness (somnolence) is listed as a very common side effect in official labeling.


Q: Is Zulin a medication that cures, or just manages, the condition?

Zulin is officially approved for the treatment of Major Depressive Disorder. This medication is designed to manage symptoms and support emotional balance, and its role is generally understood as managing the condition rather than providing a 'cure'.


Q: Why is proper adherence important when taking Zulin?

Official documents note that adherence is important. Discontinuation is required to be gradual, as stopping the drug abruptly can lead to symptoms such as dizziness, abnormal dreams, anxiety, and headache.


Q: What are the studies saying about the long-term use of Zulin?

Clinical trials established effectiveness over short periods (6 to 8 weeks), and some continuation studies support the maintenance of response for up to 40 weeks. Official regulatory documents acknowledge that comprehensive long-term safety and effectiveness data for all patient groups is not fully established.


Q: Is it common to experience mild headaches with Zulin?

Yes, according to the official adverse reaction list, Headache is classified as a Common side effect. This means it has been reported in at least 1 out of every 100 patients, but less than 1 out of 10.


Q: Does Zulin cause stomach upset?

Yes, official adverse reaction documentation confirms that specific gastrointestinal symptoms are common side effects. These include Nausea and Constipation.


Q: What patient groups are usually excluded from Zulin clinical trials?

Official documents state that the drug was not studied in and is generally not recommended for patients under 18 years of age. Clinical trials also commonly exclude patients with specific existing health conditions, such as a history of bipolar disorder or psychosis.


Q: What does the package insert say about Zulin's effectiveness?

The package insert summarizes clinical trials that established Zulin's effectiveness for treating Major Depressive Disorder compared to an inactive substance (placebo). This effectiveness was measured using standardized rating scales for mood, sleep, and anxiety.


Q: Can I take other prescription medications while using Zulin?

Yes, but many prescription medicines can interact. For instance, it is strictly prohibited (contraindicated) to take Zulin with certain drugs, such as Monoamine Oxidase Inhibitors (MAOIs). Caution is required for use with other medicines that affect serotonin levels or cause drowsiness.


Q: Can Zulin be used by breastfeeding mothers?

Official regulatory guidance states that a decision must be made to either discontinue the drug or discontinue nursing. Limited information suggests that maternal doses result in low levels of the active ingredient being transferred to breast milk.


Q: Are there specific symptoms that warrant calling a doctor immediately while on Zulin?

Immediate attention is warranted if you experience symptoms of Serotonin Syndrome, such as agitation, a rapid heartbeat, or very stiff muscles. Signs of infection, such as a sore throat or fever, are important to report immediately, as this could signal a rare blood cell disorder called Agranulocytosis.


Q: Does Zulin have any effect on mental clarity?

Because Zulin can cause somnolence (drowsiness) and sedation, official warnings indicate that it may impair judgment, thinking, and motor skills. Activities requiring mental alertness may be impaired. Caution is generally advised for tasks like driving or operating machinery.


Q: Can Zulin affect birth control pills?

Official drug interaction information suggests that taking hormonal contraceptives containing Ethinyl Estradiol may increase the blood levels of Zulin. This increase may heighten the risk or severity of Zulin's side effects.


Q: How long does Zulin stay in your system?

According to the drug's pharmacokinetic profile, the mean elimination half-life of the active ingredient generally ranges from about 20 to 40 hours. This figure represents the time it takes for half of the active ingredient to be removed from the body.


Q: Is it safe to crush or split Zulin tablets?

The Orally Disintegrating Tablets (ODT) formulation must strictly not be chewed or crushed. Conventional film-coated tablets are typically swallowed whole as per standard administration instructions.


How should Zulin be stored and disposed of?

How to Store and Dispose of Zulin?

Zulin (mirtazapine) must be stored strictly according to regulatory labeling to maintain its stability and ensure safety.

  • Storage Conditions: Keep Zulin at controlled room temperature, generally below 30 C, and protect it from light and moisture. The medicine must not be frozen or refrigerated.
  • Packaging Rules: Keep the tablets in their original package. Orally Disintegrating Tablets (ODT) are highly sensitive; they must remain in the blister pack until the moment of use and must be used immediately upon removal.
  • Child Safety: All forms of the medication must be kept out of the sight and reach of children.
  • Disposal: Do not dispose of unused or expired Zulin in household trash or wastewater. Consult a pharmacist or follow local regulatory requirements for authorized disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zulin found in:

A-Z Index: